Industry watchers already knew that Regeneron’s key new launches were hitting their marks, thanks to quarterly numbers Sanofi unveiled earlier this week. What they didn’t know was that top seller Eylea would fall short of expectations. But never fear, executives said: We're all over it.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,